首页> 外文期刊>Modern Pathology >hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies
【24h】

hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies

机译:hMLH1和MGMT失活是单克隆游戏中肿瘤发生的机制

获取原文
           

摘要

Monoclonal gammopathies are a group of disorders characterized by clonal proliferation and accumulation of immunoglobulin-producing plasma cells. Multiple myeloma and monoclonal gammopathy of undetermined significance are the most common monoclonal gammopathies; the two comprise a spectrum of disorders, ranging from a relatively benign disease, monoclonal gammopathy of undetermined significance, to a malignant disease, multiple myeloma. Aberrant promoter methylation represents a primary mechanism of gene silencing during tumorigenesis. DNA repair systems act to maintain genome integrity in the presence of replication errors, environmental insults, and the cumulative effects of aging. The methylation patterns of two genes implicated in DNA repair, O6 methylguanine DNA methyl-transferase (MGMT) and human mutL homologue1 (hMLH1) have been detected in various solid tumours. With the purpose of studying the gene silencing of MGMT and hMLH1 in plasma cell disorders, we investigated the methylation status and expression of both genes in: 29 cases of multiple myeloma; one case of plasma cell leukaemia; 13 cases of monoclonal gammopathy of undetermined significance; and two cases of polyclonal plasmacytosis, using methylation-specific polymerase-chain reaction and immunohistochemical techniques. Methylation frequencies for MGMT were 23% in multiple myeloma and 8% in monoclonal gammopathy of undetermined significance. It was 10% for hMLH1 in multiple myeloma. None of the patients diagnosed with monoclonal gammopathy of undetermined significance had hMLH1 hypermethylated. In addition, 50% of myeloma cases had a loss of hMLH1 expression, whereas silencing of MGMT was observed in 43% of myeloma and 36% of samples with monoclonal gammopathy of undetermined significance. This study indicates that repair pathway defects play a role in the pathogenesis and evolution of monoclonal gammopathies, and suggests that inactivation of hMLH1 could be implicated in multiple myeloma tumorigenesis.
机译:单克隆血友病是一组疾病,其特征在于产生免疫球蛋白的浆细胞的克隆增殖和积累。意义不明的多发性骨髓瘤和单克隆球蛋白病是最常见的单克隆球蛋白病。二者包括一系列疾病,从相对良性疾病,意义不明的单克隆丙种球蛋白病到恶性疾病,多发性骨髓瘤。异常启动子甲基化代表肿瘤发生过程中基因沉默的主要机制。 DNA修复系统可在存在复制错误,环境侮辱和衰老的累积效应的情况下维护基因组完整性。已在各种实体瘤中检测到涉及DNA修复的两个基因O6甲基鸟嘌呤DNA甲基转移酶(MGMT)和人mutL同系物1(hMLH1)的甲基化模式。为了研究MGMT和hMLH1在浆细胞疾病中的基因沉默,我们调查了29例多发性骨髓瘤患者中甲基化状态和两个基因的表达。浆细胞白血病1例; 13例意义不明的单克隆丙种球蛋白病;使用甲基化特异性聚合酶链反应和免疫组化技术的两例多克隆浆细胞增多症。在多发性骨髓瘤中,MGMT的甲基化频率为23%,而在单发性乳腺病中的甲基化频率为8%。多发性骨髓瘤中的hMLH1为10%。被诊断患有意义不明的单克隆性丙种球蛋白病的患者中,没有人的hMLH1甲基化。此外,有50%的骨髓瘤病例的hMLH1表达缺失,而在43%的骨髓瘤和36%的具有未定意义的单克隆性乳腺病的样本中,MGMT沉默。这项研究表明修复途径缺陷在单克隆gammopathies的发病机理和演变中发挥作用,并建议hMLH1的失活可能与多发性骨髓瘤的肿瘤发生有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号